Chronos Archive seal

Review checklist: Mahalia Jackson (HR-ML035)

All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments

Everything a reviewer needs to judge, gathered from the record. Release status: draft.

Review status

ReviewStatusReviewerDateNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the diagnosis by EBUS with infection excluded, the decision to complete cardiac MRI and FDG-PET before glucocorticoids, the prednisone dose and taper with methotrexate, the defibrillator decision after an inducible electrophysiology study with an ejection fraction of 47 percent, the handling of calcium and vitamin D with alendronate, atovaquone instead of trimethoprim-sulfamethoxazole with methotrexate, and the touring plan.
provenance reviewnot_startedShe died in 1972; the recent-death rule does not apply. Claims rest on The New York Times obituary, the presidential statement, PBS, Biography.com, New Orleans Historical, TheWrap and Wikipedia's summary of Goreau's biography. The cause of death and the cardiac sarcoidosis interpretation are R; everything clinical is synthetic.
safe messaging reviewnot_startedNo mental health or substance claim is made; mood screens are synthetic and below the threshold for a safety assessment. Weight is recorded as measured, without comment on her body. Her death is recorded once, without detail. No relative, spouse, colleague or historical physician is given a role in the modern episode.

Judgment calls (dossier editorial resolutions)

  1. Recent-death rule. She died in 1972, so the rule does not apply. The claims are still limited to what the fetched sources state. The Library of Congress, the Historic New Orleans Collection and the Mahalia Jackson Foundation pages, and the biographies by Laurraine Goreau and by Darden, were not read directly; the health history from Goreau is taken from Wikipedia’s summary, with TheWrap as a second source where it agrees, and is graded D with certainty “probable.”
  2. When sarcoidosis was diagnosed. The assignment described a diagnosis “reportedly in 1964.” The sources put the first diagnosis earlier: after the 1952 European tour, when a hysterectomy found granulomas (CLM-0005; Wikipedia and TheWrap). The 1964 admission is when, by Goreau’s account, her doctors told her privately of a heart attack and that “sarcoidosis was now in her heart” (CLM-0006). The modern episode therefore makes the first tissue diagnosis in a patient told years before that she had sarcoidosis, with no records, and finds cardiac involvement; this reconciles the two accounts.
  3. Index age and dates. The synthetic date of birth is October 26, 1973 (shift 62 years). The index visit on February 9, 2026 maps to February 9, 1964, when she was 52, in the year of the documented cardiac admission. All visits map to February to October 1964, within her lifetime; they are not a claim about where she was. The 1964 admission has no month in the sources, so its timeline event is dated “1964 to 1965” (it began a year of recovery) and its claims do not appear in the intake documents, which show only the 1952 history and earlier events.
  4. Cause of death and cardiac sarcoidosis (R). The sources disagree on the cause of death: a heart seizure (The New York Times), heart failure (PBS), a heart attack (Biography.com), heart complications at home (New Orleans Historical, which also conflicts on the place), and death in recovery after surgery for a bowel obstruction that TheWrap attributes to sarcoidosis (CLM-0011, disputed). That her heart disease was cardiac sarcoidosis rests on her biographer’s account of what her doctors told her in private and is recorded as a retrospective interpretation (CLM-0012, possible). The modern cardiac diagnosis is linked to both and resolves neither.
  5. Later symptoms. The eye inflammation and the cramps in her legs and hands by the late 1960s (CLM-0008) are recorded as stated; that the eye inflammation was sarcoid uveitis is not claimed. Her later high blood pressure and the diabetes that some sources mention are not claimed: the high blood pressure postdates the index date, and no fetched source documents diabetes.
  6. Weight and diet. Wikipedia records that she gained weight on tour and lost about 50 pounds during the year after 1964; TheWrap records the 50-pound loss. The modern record measures her weight and BMI (about 32) at each visit as any record would, without a weight-related diagnosis or comment on her body, and discusses diet only for steroid-related glucose and blood pressure. This is a deliberate choice to avoid stigma.
  7. Presenting problems. Exertional breathlessness and cough with hilar adenopathy (R06.09) is resolved at the consultation on February 23, 2026, when pulmonary sarcoidosis with lymph node involvement (D86.2, both_with_link) is recorded after EBUS. Palpitations with conduction disease (R00.2) is resolved on March 9, 2026, when cardiac sarcoidosis (D86.85, both_with_link) is recorded. Hypercalcemia (E83.52) resolves on treatment at the May visit. The intake documents state only what was known then.
  8. Synthetic clinical picture. All visits, results, imaging, pathology, the cardiac findings, the electrophysiology study and defibrillator, the regimen (prednisone 40 mg tapered to 7.5 mg; methotrexate 15 then 20 mg weekly), her height (170 cm) and weights are synthetic. Qualitative results (stains, cultures, lavage, interferon-gamma release assay, HIV and hepatitis tests, Holter, echocardiogram, MRI, PET, device checks, rapid viral tests) are in note and procedure text only.
  9. Defibrillator. An ICD was chosen for an ejection fraction of 47 percent with scar, nonsustained ventricular tachycardia and inducible sustained ventricular tachycardia, a Class IIa indication in the HRS consensus; dual chamber because of the conduction disease. This is a clinical judgment call for review, and the advance care planning records her wishes about deactivation.
  10. Methotrexate and pneumocystis. Atovaquone was chosen for pneumocystis prophylaxis instead of trimethoprim-sulfamethoxazole because of the interaction with methotrexate; prophylaxis stopped when prednisone fell below 20 mg. Judgment call for review.
  11. Calcium and vitamin D. Calcium supplements were stopped and avoided because of granuloma-driven hypercalcemia, bone protection used alendronate, and vitamin D was replaced at 1000 units daily only after calcium was normal, with calcium rechecked.
  12. Sick visit. Acute viral laryngitis on prednisone and methotrexate (J04.0), chosen because it is common, matters greatly to a singer, interacts with immunosuppression (no thrush, no fever, viral tests negative, treatment continued), and insinuates no undocumented real diagnosis. A concert was postponed with a promoter letter that gives no medical details.
  13. Preventive visit. A periodic adult preventive visit at 52 (CPT 99396 and 99497 in plain text): influenza and COVID-19 vaccines; PCV20, two recombinant zoster doses and the two-dose hepatitis B series already complete; mammogram ordered; colonoscopy up to date; cervical screening not indicated because examination showed no cervix after the documented hysterectomy (a synthetic finding; the extent of her real operation is not known); prediabetes with a diabetes prevention program offered; lipids without a statin; and advance care planning with an unnamed agent, including defibrillator deactivation.
  14. Focused visits. The four chronic-care follow-ups (the consultation, the cardiac diagnosis and start of treatment, nine weeks, and about six months) are documented as focused visits on the ATS 2020, ERS 2021, HRS 2014, AHA 2024, ACR glucocorticoid-induced osteoporosis and ACR methotrexate guidance, the CMID osteoporosis monograph and the CDC schedule. Synthetic findings introduced: cardiac sarcoidosis (D86.85), long-term glucocorticoid use (Z79.52), and the defibrillator (Z95.810). One protocol deviation is recorded instead of an invented result: the methotrexate blood tests due two to four weeks after starting were not done because no order was placed for the long gap between visits; no harm, since the nine-week results were normal; corrective action: standing orders every four weeks to twelve weeks, then every eight to twelve weeks, at a laboratory near home or on tour.
  15. HRS 2023 update. The assignment mentioned a 2023 HRS update; no 2023 HRS cardiac sarcoidosis statement was found on PubMed. The 2024 AHA scientific statement is cited as the current update instead.
  16. Consultation. The pulmonology referral and the consultation by Kwabena Asante-Miller, MD (a fictional consultant), on February 23, 2026, are S. The consultant answers the six referral questions in line with what the record shows afterwards: sarcoidosis confirmed by EBUS with infection excluded; organ screening and calcium handling; Holter, echocardiogram, MRI and FDG-PET before treatment (all done, showing cardiac sarcoidosis); prednisone with methotrexate; an electrophysiology study and a dual-chamber defibrillator (placed after inducible ventricular tachycardia); and the monitoring and touring plan. His advice on methotrexate blood tests every two to four weeks was not followed at first, as the nine-week visit records.
  17. Aliases and names. Her birth name, Mahala Jackson, is the only alias; “Jackson” alone is not used as an alias. Dr. Martin Luther King Jr. appears only in a claim. Her husbands, her aunt, her pianist and other associates are not named in the modern episode or given any role; her health care agent is unnamed. No other figure with a record in the dataset is named; her performances at events connected with such figures are left out for that reason.
  18. Not used. Accounts of her marriages beyond the obituary’s facts, and details of her final illness and surgery beyond CLM-0009 to CLM-0011, are not used. Her real habits (tobacco, alcohol, diet) were not researched.

Protocol deviations

Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.

VisitMeasureIntervalWhat happened
2026-05-11
Progress note 04 (C-CDA)
Methotrexate safety: blood count, liver tests and creatinineBefore starting; every two to four weeks for the first three months; then every eight to twelve weeksA deviation: the blood count, liver tests and creatinine due two to four weeks after methotrexate began were not done, because no laboratory order was placed for the long gap between visits. No harm resulted: today hemoglobin 13.1 g/dL, white cells 9.8 (raised by prednisone), lymphocytes 1.2, platelets 262, ALT 31, AST 28, alkaline phosphatase 96 U/L, albumin 4.1 g/dL, creatinine 0.92 mg/dL and eGFR 75 are normal. Corrective action: standing orders every four weeks until twelve weeks and then every eight to twelve weeks, at a laboratory near home or on tour, with a reminder to her and to the clinic

Orders and referrals without results in the record

VisitTypeItemStatusDetail
2026-02-23
Progress note 02 (C-CDA)
LaboratoryExclusion of other granulomatous causesOrderedAcid-fast and fungal stains negative; mycobacterial and fungal cultures pending, final in six to eight weeks; interferon-gamma release assay and HIV negative from the first visit
2026-02-23
Progress note 02 (C-CDA)
ExaminationHolter monitoringOrderedTomorrow
2026-02-23
Progress note 02 (C-CDA)
ImagingEchocardiogramOrderedThis week
2026-02-23
Progress note 02 (C-CDA)
ImagingCardiac MRI with late gadolinium enhancementOrderedWithin two weeks
2026-02-23
Progress note 02 (C-CDA)
ImagingCardiac FDG-PETOrderedWithin two weeks, after a 72-hour high-fat, very-low-carbohydrate diet
2026-02-23
Progress note 02 (C-CDA)
ExaminationEye examinationOrderedOphthalmology appointment next week
2026-02-23
Progress note 02 (C-CDA)
LaboratoryHepatitis B and C screeningOrderedHepatitis B surface antigen, core antibody and surface antibody, and hepatitis C antibody drawn today
2026-03-09
Progress note 03 (C-CDA)
LaboratoryExclusion of other granulomatous causesOrderedCultures no growth at three weeks; final at six to eight weeks
2026-03-09
Progress note 03 (C-CDA)
ImagingBone density (DXA) and FRAXOrderedBooked for next week
2026-03-09
Progress note 03 (C-CDA)
ReferralCardiology and electrophysiologyReferredSeen with Dr. Asante-Miller today; electrophysiology study booked for next week
2026-10-05
Progress note 07 (C-CDA)
PreventionBreast cancer screeningOrderedMammogram every two years from 40; last one three years ago; ordered today

Evidence to check

Retrospective claims (R)

ClaimStatementCertainty
CLM-0011The cause of her death is recorded differently: a heart seizure (The New York Times), heart failure (PBS), a heart attack (Biography.com), heart complications at home (New Orleans Historical), and death in recovery after surgery for a bowel obstruction, which one account attributes to sarcoidosis (Wikipedia, TheWrap).disputed
CLM-0012That her heart disease, and the heart trouble that recurred until her death, was cardiac sarcoidosis is a retrospective interpretation. It rests on the private account of her doctors in 1964 reported by her biographer; the public diagnoses were heart strain, exhaustion and heart trouble.possible

Sensitive claims

ClaimGradeStatement
CLM-0011RThe cause of her death is recorded differently: a heart seizure (The New York Times), heart failure (PBS), a heart attack (Biography.com), heart complications at home (New Orleans Historical), and death in recovery after surgery for a bowel obstruction, which one account attributes to sarcoidosis (Wikipedia, TheWrap).

Diagnoses not confirmed

None.

Notes to read

Every note in the record, with its type. All clinical content is synthetic.

Abnormal results

DateResultValueFlag
2026-02-09Lymphocyte count0.9 10*3/uL (low)Low
2026-02-09Creatinine1.08 mg/dL (high)High
2026-02-09Glucose104 mg/dL (high)High
2026-02-09Calcium10.8 mg/dL (high)High
2026-02-09Alkaline phosphatase128 U/L (high)High
2026-02-09Hemoglobin A1c5.9% (high)High
2026-02-0925-hydroxyvitamin D22 ng/mL (low)Low
2026-02-091,25-dihydroxyvitamin D84 pg/mL (high)High
2026-02-09NT-proBNP210 pg/mL (high)High
2026-02-23FVC percent predicted74% (low)Low
2026-02-23FEV1 percent predicted76% (low)Low
2026-02-23DLCO percent predicted62% (low)Low
2026-02-23Calcium10.7 mg/dL (high)High
2026-03-09Lymphocyte count0.9 10*3/uL (low)Low
2026-03-09Glucose101 mg/dL (high)High
2026-03-09Calcium10.6 mg/dL (high)High
2026-03-09Alkaline phosphatase124 U/L (high)High
2026-03-09NT-proBNP240 pg/mL (high)High
2026-05-11Glucose118 mg/dL (high)High
2026-05-11Hemoglobin A1c6.3% (high)High
2026-05-1125-hydroxyvitamin D24 ng/mL (low)Low
2026-05-11NT-proBNP140 pg/mL (high)High
2026-05-11DLCO percent predicted70% (low)Low
2026-08-24Glucose108 mg/dL (high)High
2026-08-24Hemoglobin A1c6.2% (high)High
2026-08-24DLCO percent predicted76% (low)Low
2026-10-05Total cholesterol204 mg/dL (high)High